Results 101 to 110 of about 420,375 (197)

HER2 expression in breast cancer: evidence gaps and challenges. [PDF]

NPJ Precis Oncol
Atallah NM, Quinn C, Rakha E.
europepmc   +1 more source

Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials.

JAMA Netw Open
Jänne PA, Planchard D, Goto K, Smit EF, de Langen AJ, Goto Y, Ninomiya K, Kubo T, Pérol M, Felip E, Hayashi H, Nakagawa K, Shimizu J, Nagasaka M, Pereira K, Taguchi A, Ali A, Karnoub M, Yonemochi R, Leung D, Li BT.   +20 more
europepmc   +1 more source

Antibody-drug conjugates in HER2-positive advanced or metastatic gastric cancer: a systematic review and meta-analysis. [PDF]

Front Oncol
Li J, Chen S, Chai Y, Qiu S.
europepmc   +1 more source

Clinical application and optimization strategies for antibody-drug conjugates in solid tumors. [PDF]

J Int Med Res
Qu J, Zhao X, Zhang L, Cai W, Shen M, Liu X, Wei X, Fei F.   +7 more
europepmc   +1 more source

Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression. [PDF]

Einstein (Sao Paulo)
Amarger CD, Rabello MIS, Skaf SC, Moura F, Cassoli JPB, Taranto P, Serrano Usón Junior PL, Kaliks R, Beal JR.   +8 more
europepmc   +1 more source

Alter Destiny [PDF]

, 2004
Rigopoulos, Peter
core   +1 more source

China’s Manifest Destiny [PDF]

, 2018
de Burgh, H., de Burgh, H.
core  

Letter to the Editor Re: Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06: Clinical validation of the VENTANA PATHWAY anti-HER2/neu (4B5) assay in HER2-low and HER2-ultralow breast cancer. [PDF]

ESMO Open
Horimoto Y.
europepmc   +1 more source

Idiosyncratic Drug-Induced Liver Injury and Trastuzumab Deruxtecan in Breast Cancer: A Case Report. [PDF]

Curr Oncol
Lisanti C, Della Rossa S, Zottarelli E, Vida R, Bolzonello S, Da Ros L, Zdjelar A, Cecchin E, Perin T, Puglisi F.   +9 more
europepmc   +1 more source